文献速递消化系统肿瘤

可切除与临界可切除胰腺癌的新辅助放化疗对比直接手术:荷兰随机PREOPANC试验的长期结果

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
PubMed 文献 · J Clin Oncol · 2022-01-27

这项多中心III期随机试验将246例可切除或临界可切除胰腺癌患者按1:1分配至新辅助放化疗组(119例)或直接手术组(127例)。中位随访59个月时,新辅助放化疗组总生存优于直接手术组(HR 0.73,95%CI 0.56-0.96,P=0.025),5年OS率分别为20.5%和6.5%。

要点

  • 新辅助吉西他滨为基础放化疗较直接手术改善可切除与临界可切除胰腺癌的总生存(HR 0.73)。
  • 中位生存差异仅1.4个月(15.7个月 vs 14.3个月),但5年OS率分别为20.5%和6.5%。
  • 预设亚组(包括可切除与临界可切除)中疗效一致。

核心结论

  • 在可切除与临界可切除胰腺癌中,新辅助吉西他滨为基础放化疗后手术及辅助吉西他滨较直接手术及辅助吉西他滨改善总生存。

研究设计与样本

  • 多中心III期随机试验,2013年4月24日至2017年7月25日入组,16家荷兰中心,246例可切除或临界可切除胰腺癌患者按1:1随机分配至新辅助放化疗组(n=119)或直接手术组(n=127)。
  • 新辅助放化疗为三个周期吉西他滨,第二周期期间联合36 Gy放疗分15次;再分期后手术,术后四个周期辅助吉西他滨。
  • 直接手术组手术后接受六个周期辅助吉西他滨;主要终点为意向治疗总生存;初始报告后未再收集安全性数据。

主要发现

  • 中位随访59个月,新辅助放化疗组总生存优于直接手术组(HR 0.73;95%CI 0.56-0.96;P=0.025)。
  • 中位生存新辅助放化疗组15.7个月 vs 直接手术组14.3个月,差异仅1.4个月。
  • 5年OS率新辅助放化疗组20.5%(95%CI 14.2-29.8) vs 直接手术组6.5%(95%CI 3.1-13.7)。
  • 新辅助放化疗的疗效在预设亚组中一致,包括可切除与临界可切除胰腺癌。

关键数值与推荐

  • 总生存HR 0.73(95%CI 0.56-0.96;P=0.025),新辅助放化疗组 vs 直接手术组。
  • 5年OS率新辅助放化疗组20.5%(95%CI 14.2-29.8) vs 直接手术组6.5%(95%CI 3.1-13.7)。
  • 中位生存新辅助放化疗组15.7个月 vs 直接手术组14.3个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 初始结果未显示统计学显著的总生存获益,长期结果在此报告。
  • 初始报告后未再收集安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial failed to demonstrate a statistically significant overall survival (OS) benefit. The long-term results are reported. METHODS: In this multicenter, phase III trial, patients with resectable and borderline resectable pancreatic cancer were randomly assigned (1:1) to neoadjuvant chemoradiotherapy or upfront surgery in 16 Dutch centers. Neoadjuvant chemoradiotherapy consisted of three cycles of gemcitabine combined with 36 Gy radiotherapy in 15 fractions during the second cycle. After restaging, patients underwent surgery followed by four cycles of adjuvant gemcitabine. Patients in the upfront surgery group underwent surgery followed by six cycles of adjuvant gemcitabine. The primary outcome was OS by intention-to-treat. No safety data were collected beyond the initial report of the trial. RESULTS: Between April 24, 2013, and July 25, 2017, 246 eligible patients were randomly assigned to neoadjuvant chemoradiotherapy (n = 119) and upfront surgery (n = 127). At a median follow-up of 59 months, the OS was better in the neoadjuvant chemoradiotherapy group than in the upfront surgery group (hazard ratio, 0.73; 95% CI, 0.56 to 0.96; P = .025). Although the difference in median survival was only 1.4 months (15.7 months v 14.3 months), the 5-year OS rate was 20.5% (95% CI, 14.2 to 29.8) with neoadjuvant chemoradiotherapy and 6.5% (95% CI, 3.1 to 13.7) with upfront surgery. The effect of neoadjuvant chemoradiotherapy was consistent across the prespecified subgroups, including resectable and borderline resectable pancreatic cancer. CONCLUSION: Neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol. 2022. PMID: 35084987. doi:10.1200/JCO.21.02233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。